메뉴 건너뛰기




Volumn 10, Issue 8, 1999, Pages 891-898

Recent advances in the treatment of prostate cancer

Author keywords

Brachytherapy; Chemotherapy; Hormonal therapy; Prostate cancer; Recent advances

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; EPIRUBICIN; ESTRAMUSTINE; ETOPOSIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; HYDROCORTISONE; IDARUBICIN; KETOCONAZOLE; LEUPRORELIN; MEGESTROL ACETATE; NARCOTIC ANALGESIC AGENT; NILUTAMIDE; PACLITAXEL; SURAMIN;

EID: 0032878732     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008385607847     Document Type: Review
Times cited : (25)

References (67)
  • 1
    • 0026761441 scopus 로고
    • Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens
    • Rosen MA, Goldstone L, Lapin S et al. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992; 148: 331.
    • (1992) J Urol , vol.148 , pp. 331
    • Rosen, M.A.1    Goldstone, L.2    Lapin, S.3
  • 2
    • 0020660916 scopus 로고
    • Understaging and undergrading of prostate cancer; argument for postoperative radiation as adjuvant therapy
    • Lange PH, Narayan P. Understaging and undergrading of prostate cancer; argument for postoperative radiation as adjuvant therapy. Urology 1983; 21: 113.
    • (1983) Urology , vol.21 , pp. 113
    • Lange, P.H.1    Narayan, P.2
  • 3
    • 0025679195 scopus 로고
    • Role of nerve sparing radical prostatectomy for clinical stage B2 prostate cancer
    • Bigg SW, Kavoussi LR, Catalona WJ. Role of nerve sparing radical prostatectomy for clinical stage B2 prostate cancer. J Urol 1990; 144: 1420.
    • (1990) J Urol , vol.144 , pp. 1420
    • Bigg, S.W.1    Kavoussi, L.R.2    Catalona, W.J.3
  • 4
    • 0023493310 scopus 로고
    • Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule
    • Anscher MS, Prosnitz LR. Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1987; 138: 1407.
    • (1987) J Urol , vol.138 , pp. 1407
    • Anscher, M.S.1    Prosnitz, L.R.2
  • 5
    • 0025301752 scopus 로고
    • Resection margin status in radical retropubic prostatectomy specimens: Relationship to type of operation, tumor size, tumor grade and local tumor extension
    • Jones EC. Resection margin status in radical retropubic prostatectomy specimens: Relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 1990; 144: 89.
    • (1990) J Urol , vol.144 , pp. 89
    • Jones, E.C.1
  • 6
    • 0027845218 scopus 로고
    • Down staging of localized prostate cancer by neoadjuvant therapy with flutamide and lupon: The first controlled and randomized trial
    • Labrie F, Dupon A, Cusan L et al. Down staging of localized prostate cancer by neoadjuvant therapy with flutamide and lupon: The first controlled and randomized trial. Clin Invest Med 1993; 16: 499-509.
    • (1993) Clin Invest Med , vol.16 , pp. 499-509
    • Labrie, F.1    Dupon, A.2    Cusan, L.3
  • 7
    • 0029059020 scopus 로고
    • Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2(T2bNXMO) prostate cancer
    • The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
    • Soloway MS, Sharifi R, Wajsman Z et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2(T2bNXMO) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995; 154: 424-8.
    • (1995) J Urol , vol.154 , pp. 424-428
    • Soloway, M.S.1    Sharifi, R.2    Wajsman, Z.3
  • 8
    • 0029656221 scopus 로고    scopus 로고
    • Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer
    • Gleave ME, Goldenberg SL, Jones EC et al. Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996; 155: 213-9.
    • (1996) J Urol , vol.155 , pp. 213-219
    • Gleave, M.E.1    Goldenberg, S.L.2    Jones, E.C.3
  • 9
    • 0029016831 scopus 로고
    • 2 prostate cancer: Interim results of a prospective randomize trial
    • 2 prostate cancer: Interim results of a prospective randomize trial. J Urol 1995; 154: 429.
    • (1995) J Urol , vol.154 , pp. 429
    • Van Poppel, H.1    De Ridder, D.2    Elgamal, A.3
  • 11
    • 1542714492 scopus 로고    scopus 로고
    • Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study
    • Vailancourt L, Ttu B, Fradet Y et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol 1996; 20: 86-91.
    • (1996) Am J Surg Pathol , vol.20 , pp. 86-91
    • Vailancourt, L.1    Ttu, B.2    Fradet, Y.3
  • 12
    • 0032412924 scopus 로고    scopus 로고
    • Hormonal treatment before radical prostatectomy: A three-year follow-up
    • Aus G, Abrahamsson PA et al. Hormonal treatment before radical prostatectomy: A three-year follow-up. J Urol 1998; 159 (6): 2013-6.
    • (1998) J Urol , vol.159 , Issue.6 , pp. 2013-2016
    • Aus, G.1    Abrahamsson, P.A.2
  • 13
    • 0023680206 scopus 로고
    • Adjuvant estrogen following radiation therapy for stage C carcinoma of the prostate: Long-term results of a prospective randomized trial
    • Zagars GK et al. Adjuvant estrogen following radiation therapy for stage C carcinoma of the prostate: Long-term results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1988; 14: 1085-91.
    • (1988) Int J Radiat Oncol Biol Phys , vol.14 , pp. 1085-1091
    • Zagars, G.K.1
  • 14
    • 0015749215 scopus 로고
    • The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate
    • Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126-30.
    • (1973) Cancer , vol.32 , pp. 1126-1130
    • Byar, D.P.1
  • 15
    • 0030856678 scopus 로고    scopus 로고
    • Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
    • Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
    • (1997) N Engl J Med , vol.337 , pp. 295-300
    • Bolla, M.1
  • 16
    • 0028880521 scopus 로고
    • Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
    • Pilepich MV et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45 (4): 616-23.
    • (1995) Urology , vol.45 , Issue.4 , pp. 616-623
    • Pilepich, M.V.1
  • 17
    • 0031051097 scopus 로고    scopus 로고
    • Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31
    • Pilepich MV et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15: 1013-21.
    • (1997) J Clin Oncol , vol.15 , pp. 1013-1021
    • Pilepich, M.V.1
  • 18
    • 0028173105 scopus 로고
    • The biologic basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate
    • Leibel SA, Zelefsky MJ, G. Kutcher. The biologic basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 1994; 21: 580-92.
    • (1994) Semin Oncol , vol.21 , pp. 580-592
    • Leibel, S.A.1    Zelefsky, M.J.2    Kutcher, G.3
  • 19
    • 0030657664 scopus 로고    scopus 로고
    • Cost benefit of emerging technology in localized carcinoma of the prostate
    • Perez CA et al. Cost benefit of emerging technology in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997; 39: 875-87.
    • (1997) Int J Radiat Oncol Biol Phys , vol.39 , pp. 875-887
    • Perez, C.A.1
  • 20
    • 0026778629 scopus 로고
    • Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidity
    • Soffen EM et al. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidity. Int J Radiat Oncol Biol Phys 1992; 24: 485-91.
    • (1992) Int J Radiat Oncol Biol Phys , vol.24 , pp. 485-491
    • Soffen, E.M.1
  • 21
    • 0029941575 scopus 로고    scopus 로고
    • Lateral rectal shielding reduces late rectal morbidity following high-dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a signficant dose effect
    • Lee WR et al. Lateral rectal shielding reduces late rectal morbidity following high-dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a signficant dose effect. Int J Radiat Oncol Biol Phys 1996; 35: 251-7.
    • (1996) Int J Radiat Oncol Biol Phys , vol.35 , pp. 251-257
    • Lee, W.R.1
  • 22
    • 0000624946 scopus 로고    scopus 로고
    • Three-dimensional conformal radiotherapy and dose escalation: Where do we stand?
    • Zelefsky MJ et al. Three-dimensional conformal radiotherapy and dose escalation: Where do we stand? Semin Radiat Oncol 1998; 8: 107-14.
    • (1998) Semin Radiat Oncol , vol.8 , pp. 107-114
    • Zelefsky, M.J.1
  • 23
    • 0029013018 scopus 로고
    • Clinical and biochemical evidence of control of prostate cancer at five years after external beam radiation
    • Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at five years after external beam radiation. J Urol 1995; 154: 456-9.
    • (1995) J Urol , vol.154 , pp. 456-459
    • Hanks, G.E.1    Lee, W.R.2    Schultheiss, T.E.3
  • 24
    • 0030586031 scopus 로고    scopus 로고
    • Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > 10 ng/ml
    • Hanks GE et al. Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > 10 ng/ml. Int J Radiat Oncol Biol Phys 1996; 35: 861-8.
    • (1996) Int J Radiat Oncol Biol Phys , vol.35 , pp. 861-868
    • Hanks, G.E.1
  • 25
    • 0028910506 scopus 로고
    • Advanced prostate cancer: The results of a randomized comparative trial of high-dose irradiation boosting with conformal protons compared with conventional-dose irradiation using photons alone
    • Shipley WU et al. Advanced prostate cancer: The results of a randomized comparative trial of high-dose irradiation boosting with conformal protons compared with conventional-dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995; 32: 3-12.
    • (1995) Int J Radiat Oncol Biol Phys , vol.32 , pp. 3-12
    • Shipley, W.U.1
  • 26
    • 0030456068 scopus 로고    scopus 로고
    • Should brachytherapy be considered a therapeutic option in localized prostate cancer?
    • Blasko JC et al. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin N Am 1996; 23: 633-50.
    • (1996) Urol Clin N Am , vol.23 , pp. 633-650
    • Blasko, J.C.1
  • 27
    • 0030778649 scopus 로고    scopus 로고
    • Brachytherapy for clinically localized prostate cancer. Results at seven- and eight-year follow-up
    • Ragde H, Blasko JC, Grimm PD. Brachytherapy for clinically localized prostate cancer. Results at seven- and eight-year follow-up. Semin Surg Oncol 1997; 13: 438-46.
    • (1997) Semin Surg Oncol , vol.13 , pp. 438-446
    • Ragde, H.1    Blasko, J.C.2    Grimm, P.D.3
  • 28
    • 0030947222 scopus 로고    scopus 로고
    • Long-term results of retropubic permanent I-125 implant of the prostate for clinically localized prostate cancer
    • Zelefsky MJ et al. Long-term results of retropubic permanent I-125 implant of the prostate for clinically localized prostate cancer. J Urol 1998; 158: 23-9.
    • (1998) J Urol , vol.158 , pp. 23-29
    • Zelefsky, M.J.1
  • 29
    • 0030887902 scopus 로고    scopus 로고
    • The PSA nadir that indicates potential cure after radiotherapy for prostate cancer
    • Critz FA et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 1997; 49: 322-31.
    • (1997) Urology , vol.49 , pp. 322-331
    • Critz, F.A.1
  • 30
    • 0031051524 scopus 로고    scopus 로고
    • Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer
    • Prestidge BR et al. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 31-8.
    • (1997) Int J Radiat Oncol Biol Phys , vol.37 , pp. 31-38
    • Prestidge, B.R.1
  • 31
    • 0032538069 scopus 로고    scopus 로고
    • Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    • D'Amico AV et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.
    • (1998) JAMA , vol.280 , pp. 969-974
    • D'Amico, A.V.1
  • 32
    • 0031403675 scopus 로고    scopus 로고
    • Immediate versus deferred treatment for advanced prostate cancer: Initial results of the Medical Research Council trial
    • The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer: Initial results of the Medical Research Council trial. Br J Urol 1997; 79; 235-46.
    • (1997) Br J Urol , vol.79 , pp. 235-246
  • 33
    • 0030816124 scopus 로고    scopus 로고
    • Combined androgen blockade: The gold standard for metastatic prostate cancer
    • McLead DG et al. Combined androgen blockade: The gold standard for metastatic prostate cancer. Eur Urol 1997; 32 (Suppl 3): 70-7.
    • (1997) Eur Urol , vol.32 , Issue.3 SUPPL. , pp. 70-77
    • McLead, D.G.1
  • 34
    • 0024324367 scopus 로고
    • A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
    • Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-29.
    • (1989) N Engl J Med , vol.321 , pp. 419-429
    • Crawford, E.D.1
  • 35
    • 0032497522 scopus 로고    scopus 로고
    • A comparison of bilateral orchiectomy with or without flutamide in stage D2 prostate cancer
    • Eisenberger MA. A comparison of bilateral orchiectomy with or without flutamide in stage D2 prostate cancer. N Engl J Med 1998; 339: 1036-42.
    • (1998) N Engl J Med , vol.339 , pp. 1036-1042
    • Eisenberger, M.A.1
  • 36
    • 0032556218 scopus 로고    scopus 로고
    • Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial
    • Moinpour CM et al. Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial. J Natl Cancer Inst 1998; 90: 1537-44.
    • (1998) J Natl Cancer Inst , vol.90 , pp. 1537-1544
    • Moinpour, C.M.1
  • 37
    • 0029103141 scopus 로고
    • Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients
    • Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-9.
    • (1995) Lancet , vol.346 , pp. 265-269
  • 38
    • 0031038373 scopus 로고    scopus 로고
    • Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens
    • Caubet JF et al. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49: 71-8.
    • (1997) Urology , vol.49 , pp. 71-78
    • Caubet, J.F.1
  • 39
    • 0031869236 scopus 로고    scopus 로고
    • A pilot study of intermittent androgen deprivation in advanced prostate cancer
    • Horwich A et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 1998; 81: 96-9.
    • (1998) Br J Urol , vol.81 , pp. 96-99
    • Horwich, A.1
  • 40
    • 0345060642 scopus 로고    scopus 로고
    • Intermittent hormone blockade: Optimal induction duration and predictive factors for prolonged time off hormone blockade
    • Strum SB et al. Intermittent hormone blockade: Optimal induction duration and predictive factors for prolonged time off hormone blockade. Proc ASCO 1998; 17.
    • (1998) Proc ASCO , pp. 17
    • Strum, S.B.1
  • 41
    • 0030297953 scopus 로고    scopus 로고
    • Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
    • Higano CS et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study. Urology 1996; 48: 800-4.
    • (1996) Urology , vol.48 , pp. 800-804
    • Higano, C.S.1
  • 42
    • 0028892410 scopus 로고
    • Intermittent androgen suppresion in the treatment of prostate cancer: A preliminary report
    • Goldenburg SL et al. Intermittent androgen suppresion in the treatment of prostate cancer: A preliminary report. Urology 1995; 45: 839-45.
    • (1995) Urology , vol.45 , pp. 839-845
    • Goldenburg, S.L.1
  • 43
    • 0022997273 scopus 로고
    • Intermittent endocrine therapy for advanced prostate cancer
    • Klotz LH et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546-50.
    • (1986) Cancer , vol.58 , pp. 2546-2550
    • Klotz, L.H.1
  • 44
    • 0031010962 scopus 로고    scopus 로고
    • Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate
    • Brufsky A et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997; 49: 913-20.
    • (1997) Urology , vol.49 , pp. 913-920
    • Brufsky, A.1
  • 45
    • 0344630038 scopus 로고    scopus 로고
    • Secondary hormonal responses after initial peripheral androgen ablation therapy with finasteride and flutamide in advanced prostate cancer
    • Oh W et al. Secondary hormonal responses after initial peripheral androgen ablation therapy with finasteride and flutamide in advanced prostate cancer. Proc ASCO 1998; 17.
    • (1998) Proc ASCO , pp. 17
    • Oh, W.1
  • 46
    • 4243465490 scopus 로고    scopus 로고
    • Bicalutamide monotherapy versus flutamide plus gosrelin in prostate cancer patients. Preliminary results of an Italian Prostate Cancer Group Study
    • Boccardo F et al. Bicalutamide monotherapy versus flutamide plus gosrelin in prostate cancer patients. Preliminary results of an Italian Prostate Cancer Group Study. Proc ASCO 1997; 16.
    • (1997) Proc ASCO , pp. 16
    • Boccardo, F.1
  • 47
    • 85037933923 scopus 로고    scopus 로고
    • Improvements in subjective response in patients with advanced prostate cancer treated with 'casodex' (bicalutamide) 150 mg mono-therapy compared with castration
    • Tyrell CJ et al. Improvements in subjective response in patients with advanced prostate cancer treated with 'casodex' (bicalutamide) 150 mg mono-therapy compared with castration. Proc ASCO 1998; 17.
    • (1998) Proc ASCO , pp. 17
    • Tyrell, C.J.1
  • 48
    • 0030861185 scopus 로고    scopus 로고
    • Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer
    • Pummer K et al. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997; 32 (Suppl 3): 81-5.
    • (1997) Eur Urol , vol.32 , Issue.3 SUPPL. , pp. 81-85
    • Pummer, K.1
  • 49
    • 0030933345 scopus 로고    scopus 로고
    • Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multi-center study of ochiectomy alone versus orchiectomy plus estramustine phosphate
    • Janknegt RA et al. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multi-center study of ochiectomy alone versus orchiectomy plus estramustine phosphate. Urology 1997; 49: 411-20.
    • (1997) Urology , vol.49 , pp. 411-420
    • Janknegt, R.A.1
  • 50
    • 0345060640 scopus 로고    scopus 로고
    • Androgen deprivation + four courses of fixed-schedule suramin in D2 prostate cancer patients: A Southwest Oncology Group phase II study
    • Hussain M et al. Androgen deprivation + four courses of fixed-schedule suramin in D2 prostate cancer patients: A Southwest Oncology Group phase II study. Proc ASCO 1998; 17.
    • (1998) Proc ASCO , pp. 17
    • Hussain, M.1
  • 51
    • 17144469967 scopus 로고    scopus 로고
    • Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer
    • Dawson NA et al. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997; 15: 1470-7.
    • (1997) J Clin Oncol , vol.15 , pp. 1470-1477
    • Dawson, N.A.1
  • 52
    • 0031017228 scopus 로고    scopus 로고
    • Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
    • Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 1997; 15: 382-8.
    • (1997) J Clin Oncol , vol.15 , pp. 382-388
    • Small, E.J.1    Vogelzang, N.J.2
  • 53
    • 0030971169 scopus 로고    scopus 로고
    • Antiandrogen withdrawal syndrome with nilutamide
    • Huan SD, Gerridzen RG et al. Antiandrogen withdrawal syndrome with nilutamide. Urology 1997; 49: 632-4.
    • (1997) Urology , vol.49 , pp. 632-634
    • Huan, S.D.1    Gerridzen, R.G.2
  • 54
    • 0030999075 scopus 로고    scopus 로고
    • Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
    • Small EJ et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157: 1204-7.
    • (1997) J Urol , vol.157 , pp. 1204-1207
    • Small, E.J.1
  • 55
    • 0030695382 scopus 로고    scopus 로고
    • Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortizone in patients with advanced prostate carcinoma
    • Small EJ et al. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortizone in patients with advanced prostate carcinoma. Cancer 1997; 80: 1755-9.
    • (1997) Cancer , vol.80 , pp. 1755-1759
    • Small, E.J.1
  • 56
    • 18244419285 scopus 로고    scopus 로고
    • Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPRCA study 9002
    • Iverson P et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPRCA study 9002. J Urol 1997; 157: 929-34.
    • (1997) J Urol , vol.157 , pp. 929-934
    • Iverson, P.1
  • 57
    • 0030747033 scopus 로고    scopus 로고
    • Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
    • Hudes GR et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15: 3156-63.
    • (1997) J Clin Oncol , vol.15 , pp. 3156-3163
    • Hudes, G.R.1
  • 58
    • 0030965020 scopus 로고    scopus 로고
    • A phase II study of oral idarubicin as treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time
    • Schhmid HP et al. A phase II study of oral idarubicin as treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Cancer 1997; 79: 1703-9.
    • (1997) Cancer , vol.79 , pp. 1703-1709
    • Schhmid, H.P.1
  • 59
    • 0030711034 scopus 로고    scopus 로고
    • Oral estramustine and oral etoposide for hormone-refractory prostate cancer
    • Dimopoulos MA et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997; 50: 754-8.
    • (1997) Urology , vol.50 , pp. 754-758
    • Dimopoulos, M.A.1
  • 60
    • 0030782928 scopus 로고    scopus 로고
    • A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer
    • Pienta KJ et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 1997; 50: 401-7.
    • (1997) Urology , vol.50 , pp. 401-407
    • Pienta, K.J.1
  • 61
    • 0030835839 scopus 로고    scopus 로고
    • Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer
    • Colleoni M et al. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer Am J Clin Oncol 1997; 20; 383-6.
    • (1997) Am J Clin Oncol , vol.20 , pp. 383-386
    • Colleoni, M.1
  • 62
    • 0030927778 scopus 로고    scopus 로고
    • Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: A phase II study
    • Hernes EH et al. Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: A phase II study. Br J Cancer 1997; 76: 93-9.
    • (1997) Br J Cancer , vol.76 , pp. 93-99
    • Hernes, E.H.1
  • 63
    • 0030763677 scopus 로고    scopus 로고
    • Suramin/epidoxorubicin association in hormone-refractory prostate cancer: Preliminary results of a pilot phase II study
    • Miglietta L et al. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: Preliminary results of a pilot phase II study. J Cancer Res Clin Oncol 1997; 123: 407-10.
    • (1997) J Cancer Res Clin Oncol , vol.123 , pp. 407-410
    • Miglietta, L.1
  • 64
    • 0030997896 scopus 로고    scopus 로고
    • Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer
    • Raghavan D et al. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 1997; 33: 566-74.
    • (1997) Eur J Cancer , vol.33 , pp. 566-574
    • Raghavan, D.1
  • 65
    • 17444436904 scopus 로고    scopus 로고
    • Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer
    • Pienta KJ, Smith DC. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Semin Oncol 1997; 24 (Suppl 15): 72-7.
    • (1997) Semin Oncol , vol.24 , Issue.15 SUPPL. , pp. 72-77
    • Pienta, K.J.1    Smith, D.C.2
  • 66
    • 0031431760 scopus 로고    scopus 로고
    • Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer
    • Ellerhorst JA et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 1997; 3: 2371-6.
    • (1997) Clin Cancer Res , vol.3 , pp. 2371-2376
    • Ellerhorst, J.A.1
  • 67
    • 0001022989 scopus 로고    scopus 로고
    • Superiority of suramin + hydrocortisone over placebo + hydrocortisone: Results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer
    • Small EJ et al. Superiority of suramin + hydrocortisone over placebo + hydrocortisone: Results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer. Proc ASCO 1998; 17.
    • (1998) Proc ASCO , pp. 17
    • Small, E.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.